INTRODUCTION
Breast cancer (BC) is a heterogeneous disease that varies greatly with regard to morphology and clinical course. Multiple clinical and pathologic parameters (such as patient age; tumor size and histologic grade; lymph node metastases; and estrogen receptor [ER] , progesterone receptor [PR] , and human epidermal growth factor receptor 2 [HER2] status) are established prognostic factors. In the past decade, several multigene assays have been developed and have demonstrated prognostic value in patients with early-stage BC. [1] [2] [3] [4] To the best of our knowledge, the 21-gene expression assay (Oncotype Dx; Genomic Health, Redwood City, Calif) is the BC multigene assay most widely used in the United States. 5 The 21-gene expression assay uses reverse transcriptase-polymerase chain reaction to evaluate the expression of 16 cancer-related genes and 5 reference genes in patients with BC. 3 The resulting score (recurrence score [RS] ), derived from the reference-normalized expression of the 16 cancer-related genes, quantifies the risk of distant recurrence at 10 years and the benefit of chemotherapy in patients treated with tamoxifen. 3 The RS is a continuous variable that has been divided into 3 categories: low risk (RS <18), intermediate risk (RS of [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , and high risk (RS 31). 3 The predictive value of the assay for the usefulness of adding chemotherapy to treatment with tamoxifen has been partially validated by retrospective analyses of samples from randomized clinical trials. 4, 6 The Oncotype DX RS predicted the magnitude of chemotherapy benefit in 651 patients with ER-positive, lymph node-negative BC who were treated with tamoxifen with or without chemotherapy and who were enrolled in the National Surgical Adjuvant Breast and Bowel Project B20 trial. 4 Analysis of a subset of patients in the SWOG 8814 trial found that the predictive and prognostic value of Oncotype DX RS also applies to patients with ER-positive, lymph nodepositive BC. 6 The American Society of Clinical Oncology and the National Comprehensive Cancer Network currently include the Oncotype DX RS in their recommendations for patients with early-stage, ER-positive, HER2-negative BC (ER1/HER2-BC). 7, 8 Two prospective randomized trials, TAILORx (Trial Assigning IndividuaLized Options for treatment [Rx] ) and RxPONDER (Rx for Positive Lymph node, Endocrine Responsive breast cancer), aim to further validate the predictive value of the Oncotype DX RS.
9-11 TAILORx was specifically designed to evaluate the benefit of chemotherapy in patients with lymph node-negative, ER1/HER2-BC with an Oncotype DX RS of 11 to 25 (the TAILORx definition of an "intermediate" RS). 9, 10 Patients with an RS of 11 to 25 are randomized to receive hormonal therapy with or without chemotherapy. 9, 10 The lower category thresholds were selected to minimize the risk of omitting chemotherapy. 10 Patients with an RS of 0 to 10 (TAILORx definition of a "low" RS) receive hormonal therapy alone. Patients with an RS 26 (the TAILORx definition of a "high" RS) receive hormonal therapy plus chemotherapy. The results of TAILORx to date have confirmed an extremely low risk of disease recurrence in patients with an RS of 0 to 10, with 99.3% of patients found to be free from distant recurrence of BC at 5 years. 10 To our knowledge to date, no prospective data are available for patients with an RS of 11 to 25 and the risk for patients with an RS in the range between the conventional threshold (RS of 18) and the tested one (RS of 11) is unclear. 12 The objectives of the current study were: 1) to evaluate outcomes in a large cohort of unselected, consecutive patients with early-stage, lymph node-negative, ER1/ HER2-BC and an Oncotype DX RS <18 who were treated at the study center and for whom the Oncotype DX RS was prospectively integrated in the treatment management decision; and 2) to characterize the clinicopathological features of those patients who developed distant metastasis in this cohort.
MATERIALS AND METHODS

Study Patients
Through a search of our institutional database, we identified patients with ER-positive and/or PR-positive, HER2-negative, lymph node-negative, invasive BC who received surgical and medical treatment at the study center between September 2008 and August 2013. At the study institution, all lymph node-negative, ER-positive and/or PR-positive, HER2-negative invasive BCs measuring 0.5 cm in patients medically suitable for chemotherapy and who would potentially agree to such treatment have been routinely submitted for 21-gene expression assay using the standard commercial test since September 2008. Some ER-positive and/or PR-positive, HER2-negative BCs measuring <0.5 cm in size are also submitted for testing on specific request by the treating clinician. Patients with lymph nodes containing isolated tumor cells (pN0(i1)) according to the American Joint Committee on Cancer staging system 13 were included in the study. All patients with tumors that failed testing for technical reasons were excluded from the study.
We recorded patient age at the time of diagnosis of BC, tumor size, 21-gene expression assay result, patient treatment, and outcome. If a patient had multiple ipsilateral foci of invasive carcinoma or bilateral carcinomas, we recorded the size of the largest tumor and the highest RS. We identified patients with distant metastases through a query of the institutional database. The Institutional Review Board approved the study.
Statistical Analysis
Clinicopathologic characteristics of the cohort are summarized using descriptive statistics for the cohort overall. The clinical outcome of interest was distant metastasis-free survival, which is defined as the time period from the diagnosis of BC to the confirmation of a distant metastasis or death from any cause.
14 This outcome was described using Kaplan-Meier methods. Due to the small number of events, all analyses were descriptive and exploratory with no formal statistical analysis performed.
RESULTS
We identified 1406 consecutive patients who were treated at the study center during the study period with stage I and II lymph node-negative (including pN0(i1); 74 patients), ER1/HER2-BC and available 21-gene expression assay results. Of these, 510 patients (36%) had an Oncotype DX RS of 0 to 10 and 896 (64%) had an RS of 11 to 17. The clinicopathologic characteristics of the 1406 patients are summarized in Table 1 . The median age at the time of BC diagnosis was 56 years (range, 22-90 years). Only 63 patients (4%) were aged <40 years at the time of diagnosis of BC, 332 patients (24%) were aged 40 to 49 years, and 1011 patients (72%) were aged 50 years. The median tumor size was 1.2 cm (range, 0.3-5.8 cm).
Overall, 990 patients (70%) underwent breastconserving surgery and 416 (30%) underwent a mastectomy. Among patients who underwent breast-conserving surgery, 937 (95%) received radiotherapy. A total of 1361 patients (97%) received endocrine therapy, and 170 (12%) received chemotherapy. The median follow-up was 46 months (range, 1-85 months). Six patients (0.4%) developed distant metastases. One patient (0.1%) died of disease 64 months after a BC diagnosis, 6 patients died of other causes, and 4 patients died of unknown causes.
Patients With a Low RS (<18) and Distant Metastases
Six of the 1406 patients (0.4%) developed distant metastases within 5 years of the initial diagnosis of BC. The clinicopathologic characteristics of these 6 patients are listed in detail in Table 2 . Only 1 patient was in the group with an RS of 0 to 10 (RS of 5), and 5 patients were in the group with an RS of 11 to 17. Pathologic confirmation of metastatic BC was obtained for all 6 patients. None of the 6 patients developed locoregional recurrent disease, and none was enrolled in the TAILORx or RxPONDER trials.
Patients With an RS of 11 to 17 and Distant Metastases
Of the 896 patients in the group with an RS of 11 to 17, 5 (0.6%) developed distant metastasis. Three of the 5 patients with metastases were aged <40 years at the time of BC diagnosis, and 4 were premenopausal. In this consecutively accrued and unselected cohort of patients with lymph node-negative, ER1/HER2-BC and an RS of 11 to 17, the absolute incidence of distant metastases among patients with BC diagnosed at age <40 years was 7.1% (3 of 42 patients), whereas the absolute incidence of distant metastases among patients aged 40 years at diagnosis was 0.2% (2 of 854 patients). The median follow-up in patients diagnosed with BC at age <40 years versus aged 40 years was comparable (45.5 months vs 45.8 months; P 5 .5565). The median tumor size among patients with or without distant metastases was 2.1 cm and 1.2 cm, respectively. Treatment modalities, including the type of surgery (breast-conserving surgery vs mastectomy), radiotherapy, endocrine therapy, and chemotherapy were similar in patients with or without distant metastasis in this cohort.
Taking into account the follow-up time, the Kaplan-Meier estimates of distant metastasis-free survival overall and by age are shown in Figure 1 . These graphs include deaths due to any cause as an event.
DISCUSSION
The 21-gene expression assay is increasingly included in the evaluation of patients with early-stage ER1/HER2-BC. 15, 16 Multiple studies have assessed its impact on treatment decision making in patients with BC, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] reporting a change in chemotherapy recommendations in >30% of patients. 17, 24 In particular, patients with BC of low RS receive adjuvant endocrine therapy but no chemotherapy. In the current study, we evaluated the characteristics of patients with lymph node-negative, ER1/HER2-BC of low RS who developed distant metastases to identify factors associated with distant recurrence in this cohort, in whom chemotherapy may not be routinely recommended.
The overall distant recurrence-free survival rate for patients with lymph node-negative, ER1/HER2-BC and a low RS (<18) treated at the study center was Abbreviations: AWD, alive with disease; BCS, breast-conserving surgery; BSO, bilateral salpingo-oophorectomy; BTM, bilateral total mastectomy; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; DCIS, ductal carcinoma in situ; DOD, dead of disease; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LVI, lymphovascular invasion; PR, progesterone receptor; RS, recurrence score; RT, radiotherapy; TM, total mastectomy. a This patient also had 2 foci of ILC, measuring 0.6 cm and 0.2 cm, respectively. b This patient declined hormonal treatment.
99.6%. Distant metastases developed in 0.4% of 1406 unselected consecutive patients in this group. Two other studies have reported outcome data in large patient populations treated based on the 21-gene RS and found a similar incidence of distant recurrence and BC-specific mortality in patients with a low RS. 27, 28 Only 1 of the 6 patients with distant metastasis in the current study had a tumor with an RS <11. The rate of distant metastasis in the group of individuals with an RS of 0 to 10 was very low (1 of 510 patients; 0.2%), which is consistent with the TAILORx results in patients with BC with an RS of 0 to 10 as reported by Sparano et al. 10 Because TAILORx used a lower threshold (RS <11) rather than an RS of 18 to select patients for endocrine therapy alone, it is now an open question as to whether higher-risk patients within the historical low-risk category have a similar or significantly higher risk. 12 Until the randomized cohort in TAILORx (RS of [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] is reported, this clinically relevant question will not be definitively answered. In the cohort of 896 patients in the current study with an RS of 11 to 17, 873 patients (97%) received endocrine therapy and 148 patients (17%) received chemotherapy despite the low RS. Distant recurrence developed in 5 of 896 patients (0.6%) at a median follow-up of 46 months. On exploratory analysis, the results of the current study suggest that age <40 years may be a prognostic factor in patients with lymph node-negative, ER1/HER2-BC with an RS of 11 to 17.
Paik et al analyzed the impact of age and tumor size on the risk of distant recurrence. 3 They reported that patients aged <50 years had higher distant recurrence rates at 10 years (21.1% vs 12.3%, respectively; P 5 .004) and that patients with tumors measuring 2 cm had higher rates of distant recurrence than patients with smaller tumors (17.5% vs 13.3%, respectively; P 5 .06). However, age and tumor size lost statistical significance if the 21-gene expression assay result was added to the model. 3 In the study by Paik et al, 3 age 50 years was used as a cutoff for the analysis, and no data were provided on the comparative analysis using other age thresholds. We also found no demonstrable difference in distant metastasisfree survival using an age cutoff of 50 years. However, the data from the current study suggested that patients aged <40 years at the time of BC diagnosis have higher rates of distant recurrence. We noted that there were only 16 patients who were aged <40 years among the group with a low RS score in the study by Paik et al, 3 whereas the current study cohort included 63 patients aged <40 years.
Recent results from a larger sample from the Surveillance, Epidemiology, and End Results database do not confirm decreased survival in women aged <40 years with a low RS, but to the best of our knowledge the completeness of ascertainment of chemotherapy use in this group is uncertain. 28 Prospective studies such as TAILORx will provide more definitive information regarding the question of whether young age remains an independent prognostic factor in women with a low RS.
The current study identified 6 patients with lymph node-negative, ER1/HER2-BC and low 21-gene expression assay results (RS of 0-17) who developed distant recurrence within 5 years of their BC diagnosis. The population in the current study was unique in that it consisted of a very large, unselected, and consecutively accrued cohort of patients treated at a single institution, and for whom the 21-gene expression assay result was prospectively included in the treatment planning. The results of the current study suggest that age <40 years may be a negative prognostic factor, even in patients with a low 21-gene expression assay score. Studies with a greater number of events are needed to determine whether young age remains significant after adjusting for other variables. The current study has several limitations. First, the study center is a tertiary academic institution with a predominant population of higher socioeconomic status and with screen-detected BC. Therefore, the results might not apply to different patient populations. Nonetheless, the current study provides a large unselected cohort of patients with clinical follow-up. Second, not all patients in the current study had 5 years of follow-up due to the relatively recent adoption of the 21-gene expression assay. We will continue to follow this cohort of patients and obtain outcome information with long-term follow-up. Nevertheless, the rate of distant metastases in patients aged <40 years obtained to date will not decrease. Third, the current study was exploratory and descriptive, because the statistical analysis was limited by the low number of events. However, the current study findings are hypothesis-generating, and mandate the analysis of distant recurrence in relation to age <40 years when the data from large, prospective, randomized trials become available.
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